288 related articles for article (PubMed ID: 18855578)
1. Recent advances in Hsp90 inhibitors as antitumor agents.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
[TBL] [Abstract][Full Text] [Related]
2. Hsp90: an emerging target for breast cancer therapy.
Beliakoff J; Whitesell L
Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
[TBL] [Abstract][Full Text] [Related]
3. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
4. Targeting multiple signal transduction pathways through inhibition of Hsp90.
Zhang H; Burrows F
J Mol Med (Berl); 2004 Aug; 82(8):488-99. PubMed ID: 15168026
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
6. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
7. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
8. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
9. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
11. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 as a drug target: some like it hot.
Banerji U
Clin Cancer Res; 2009 Jan; 15(1):9-14. PubMed ID: 19118027
[TBL] [Abstract][Full Text] [Related]
15. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
17. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
18. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
19. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Choi HK; Lee K
Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]